Detalhe da pesquisa
1.
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.
Am J Drug Alcohol Abuse
; 49(1): 109-122, 2023 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630319